TMEM50B

Across TCGA pan-cancer cohorts, TMEM50B Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TMEM50B data layer compared with 19 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TMEM50B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TMEM50B expression acts as an unfavorable survival marker.

LIHC, SKCM, and CHOL are the cancer types where TMEM50B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.013	0.784	<.001	12	view →
SKCM	DFS	Median	All	0.136	0.737	.005	12	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

TMEM50B–LIHC (OS)

Open the LIHC breakdown →